Max and Novartis Mark 25 Years of Access Innovation for Cancer
In 2001, The Max Foundation partnered with the pharmaceutical corporation Novartis to develop an international treatment access program for people living with chronic myeloid leukemia (CML). Since then, we’ve helped thousands of patients in low- and middle-income countries access life-extending diagnostics, medication, and support services. A lot has changed over the years, but our focus….




